<DOC>
	<DOC>NCT00653341</DOC>
	<brief_summary>The primary objective of this study is to compare the percentage of subjects who reach the target HbA1c level (&lt; or = 7.0% at endpoint) and do not experience symptomatic nocturnal hypoglycemia during treatment with insulin glargine or NPH human insulin.</brief_summary>
	<brief_title>Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Insulin naïve subjects with type 2 diabetes treated with oral hypoglycemic agents Body mass index between 26 and 40 kg/m2 HbA1c between 7.5% and 10.0% Fasting plasma glucose &gt;7.8 mmol/L and fasting Cpeptide &gt; or =0.25 nmol/L</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>insulin naive</keyword>
</DOC>